TITLE

In two years, an abortion pill in America

PUB. DATE
May 1994
SOURCE
U.S. News & World Report;5/30/94, Vol. 116 Issue 21, p12
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Reports that after nearly a decade of acrimonious battle, Europe's RU 486 abortion pill is coming to America. The French firm that makes the drug, Roussel Uclaf, agreed to donate its patent to the Population Council, a nonprofit contraceptive research organization in New York that will find an American manufacturer. Studies conducted on the pill; Furor over the pill's use to induce abortions; Possibility that it may be able to treat various illnesses.
ACCESSION #
9405257506

 

Related Articles

  • RU 486: The science and the politics.  // Women's International Network News;Winter91, Vol. 17 Issue 1, p30 

    Reports on the policies on Ru 486, an abortion pill in France. Clinical experience with the pill; Availability; Chances that the pill will be marketed in the United States.

  • Versatile pill.  // New Scientist;6/15/91, Vol. 130 Issue 1773, p19 

    Reveals that RU 486 is an affective contraceptive when taken within 72 hours of having sex, according to researchers at the University of Edinburgh. `Morning after' regimen; The YUZPE formula (combination of estrogen and progesterone).

  • What you can learn from my RU-486 abortion. Howey, Noelle // Self;Apr2000, Vol. 22 Issue 4, p97 

    Presents comments from American women who have tried using RU-486 or Mifeprex, the famed French abortion pill. Advantages of the drug over surgical abortion; Facts about Mifeprex.

  • The Contraceptive Potential of Daily Low-Dose Mifepristone. Baird, D. T. // Fertility Weekly;5/20/2002, p8 

    Presents a research in China on the efficacy of low daily doses of mifepristone as an estrogen-free oral contraceptive pill. Inhibition of ovulation; Development of novel estrogen-free oral contraceptive pill; Inhibition of ovulation and disruption endometrial function.

  • A choice image. Yamey, Gavin // BMJ: British Medical Journal (International Edition);06/16/2001, Vol. 322 Issue 7300, p1496 

    Previews a United States advertising campaign for mifepristone, an early pregnancy abortion pill. Description of the ad; Thoughts of Operation Rescue, an antiabortion group; Efforts of antiabortion activists to prevent women from finding out about the drug, according to such pro-choice groups...

  • Effects of mifepristone on proliferation and apoptosis of human endometrium in new users of medroxyprogesterone acetate. John K. Jain; Aimin Li; Wangrong Yang; Parviz Minoo; Juan C. Felix // Human Reproduction;Mar2006, Vol. 21 Issue 3, p798 

    BACKGROUND: Mifepristone has been demonstrated to decrease breakthrough bleeding (BTB) in users of progestin-only contraceptives. METHODS: Endometrial biopsies were collected from 50 normal cycling women who were new users of depot medroxyprogesterone acetate (DMPA) randomized to receive either...

  • Counteroffensive Launched on RU-486. Guthrie, Stan // Christianity Today;06/11/2001, Vol. 45 Issue 8, p58 

    Discusses the concern over the approval and use of RU-486 abortion pill in the United States. What the accelerated approval of the pill includes; Trade name of RU-486; How the pill acts on a pregnant woman's body.

  • Low dose of Mifepristone used postcoitally is effective in preventing pregnancy. Estrin, D.J. // International Family Planning Perspectives;Sep99, Vol. 25 Issue 3, p156 

    Reveals that a 10 mg dosage of mifepristone is effective as an emergency contraceptive treatment, even if the delay between unprotected intercourse and treatment is as long as five days. Delay in menstruation in women who take the drug; Linking of dosage to length of delay in the onset of next...

  • Novel Gene Switches for Targeted and Timed Expression of Proteins of Interest. Vilaboa, Nuria; Fenna, Mary; Munson, John; Roberts, Stephen M.; Voellmy, Richard // Molecular Therapy;Aug2005, Vol. 12 Issue 2, p290 

    Abstract: This article reports on the construction and analysis in vitro and in vivo of novel gene switches that can be used to achieve spatial as well as temporal control over the expression of a transgene of interest. The switches are expected to be functional in virtually any tissue and cell...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics